is associated with the early to mid-term mortality of patients with VADs as we have consistently observed. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Considering implantable continuous-flow VADs have less device-related complications, preoperative patients' conditions are becoming more important for the long-term prognosis after VAD implantation.
Thus far, several risk scoring systems by preoperative parameters have been proposed to estimate early to mid-term prognosis after LVAD implantation. 3-7, 13 However, those scoring results may vary among physicians or institutes, because these risk scores include considerable number of subjective or interventional factors. We here constructed a new risk scoring system for 1-year mortality after LVAD implantation with parameters as objective as possible to avoid such inter-caregiver discrepancies.
Methods

Patient Population
We experienced consecutive 65 patients who had received LVADs or biventricular assist devices (BiVADs) between November 2002 and June 2010 and had been followed at least for 1 year at the University of Tokyo Hospital. Of these, 6 patients were excluded because of insufficient data or censored because of HTx abroad, and we enrolled 59 patients with VADs (EVAHEART, 4; Jarvik 2000, 3; DuraHeart, 2; HeartMate II, 1; NIPRO, 49) in this study. All 10 implantable VADs were inserted under clinical trials. All patients received optimal medical therapy consisting of β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone antagonists, and diuretics as tolerated before implantation of VADs. Cardiac resynchronization therapy (CRT) with a defibrillator was performed if indicated. Intra-aortic balloon pumping (IABP), percutaneous cardiopulmonary support (PCPS), continuous hemodiafiltration (CHDF), or mechanical ventilation was executed on the basis of the physician's decision before LVAD insertion. Timing of VAD implantation was determined if the patient developed cardiogenic shock or there was a progressive decline of end-organ function in spite of maximal treatment described above. Some patients required a right VAD (RVAD) in addition to LVAD perioperatively. RVAD therapy included the implantation of an extracorporeal NIPRO VAD to right ventricle (RV) or right atrium and/or the temporary RV assist with an extracorporeal membranous oxygenation system. Every patient had already been listed for HTx or was considered as a future candidate for HTx at the time of LVAD implantation. Written informed consent was obtained from patients and/or family members before implantation. A retrospective analysis of preoperative clinical, echocardiographic, laboratory, and hemodynamic data was performed to determine the risk factors of 1-year survival after implantation of VADs and to construct a new risk scoring system. The study protocol was approved by the Ethics Committee of Graduate School of Medicine, the University of Tokyo [application number 779 (1)].
Variables Evaluated
Clinical data included patients' demographics and the needs for mechanical support (eg, PCPS, IABP, CHDF, mechanical ventilation). Laboratory data and echocardiographic parameters were obtained <24 h before implantation of VADs. Valve insufficiency was graded as mild, 1; moderate, 2; or severe, 3. Hemodynamic data were obtained less than 1 week before implantation of VAD. All echocardiography and hemodynamic studies were performed before extracorporeal circulatory sup-port such as PCPS or CHDF. We defined 1-year mortality as the primary outcome.
Previous Risk Scores
The Columbia score was constructed by Rao et al. using the cohort data of BTT patients with HeartMate VE. 7 They assigned scores to 5 preoperative risk factors to predict perioperative mortality (ie, mechanical ventilation, 4; postcardiotomy shock, 2; previous VAD operation, 2; central venous pressure (CVP) >16 mmHg, 1; prothrombin time >16 s, 1).
The Leitz-Miller (LM) score was developed by Leitz et al using the cohort data from destination therapy with a Heart-Mate XVE, in which they defined 9 preoperative risk factors that predicted in-hospital mortality and assigned points: platelets <14.8×10 4 /μl, 7; albumin <3.3 g/dl, 5; international normalized ratio of prothrombin time >1.1, 4; vasodilator therapy, 4; mean pulmonary artery pressure <25 mmHg, 3; aspartate aminotransferase >45 IU/L, 2; hematocrit <34%, 2; serum urea nitrogen >51 mg/dl, 2; and no use of intravenous inotropic agent, 2. 4 The Acute Physiology And Chronic Health Evaluation (APACHE) II score was published first by Knaus et al, based on data from severe heart failure patients in an intensive care unit. 6 It consisted of 13 preoperative factors containing vital signs, serum electrolytes, renal data, and blood count data. Gracin et al later applied this scoring system to a cohort of 31 BTT patients with a HeartMate VE. 14 The Seattle Heart Failure Model (SHFM) was developed by Levy et al from the data of New York Heart Association (NYHA) class IIIB or IV patients, which was calculated from age, vital signs, medications, serum electrolytes, blood counts, and utilization of CRT. 3 They also updated the SHFM score for LVAD candidates by adding variables such as usage of inotropes, IABP, or mechanical ventilation. 15 We used their website (http://depts.washington.edu/shfm) to estimate our patients' survival rates.
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) stratified patients with stage D heart failure into 7 categories on the basis of clinical severity. 5 We assigned profile 1 to those who were supported by PCPS or were dependent on IABP. Patients who received elective IABP insertion to stabilize hemodynamics prior to planned VAD implantation were classified into profile 2, as in our previous study. 11 All patients with VADs recruited in our study were assigned to profile 1 or 2.
Statistical Analysis
Continuous variables of deceased and alive patients were compared by unpaired t-test or Mann-Whitney test as appropriate. Categorical variables of deceased and alive patients were compared by chi-square test or Fisher's exact test as appropriate. Univariable and multivariable analyses with a logistic regression model were performed to calculate adjusted odds ratio (OR) and 95% confidence interval (CI) to assess the influence of each preoperative variable to the 1-year mortality after LVAD implantation. Variables that were found to be significant (P<0.05) in the univariable analysis of baseline characteristics and laboratory measurements were entered into the multivariable analysis. Considering the results of univariable and multivariable analyses, weighted scores were allocated to each selected variable on the basis of each OR, and we defined a summation of scores as a new risk scoring system (ie, the TODAI VAD score [TVAD score]). In constructing categorical variables from continuous data, a cut-off point was obtained by receiver-operating characteristic (ROC) analysis with JMP9 Novel Risk Score Before LVAD Implantation (SAS Institute Inc, Cary, NC, USA). A ROC curve of the TVAD score was created, by which the area under the curve (AUC) for the score was calculated, and that AUC was compared with those of previously published risk scores, including Columbia, LM, APACH II, SHFM, and INTERMACS. Kaplan-Meier survival analysis was performed to evaluate 1year survival after implantation of LVADs on 3 strata of the TVAD score, and survivals among these strata were compared by log-rank test. A univariable analysis with Cox hazard model was also adopted to 3 strata of the TVAD score. Unless otherwise specified, all data are expressed as mean ± standard de-viation. Probability was 2-tailed, with P<0.05 regarded as statistically significant. All statistical analysis was calculated with PASW Statics 18 (SPSS Inc, Chicago, IL, USA) except for ROC analyses with JMP9.
Results
Baseline Characteristics of Enrolled Patients (Table 1)
We enrolled 59 patients who had received VADs (extracorporeal pulsatile VAD, 49; implantable continuous-flow VAD, 10) between November 2002 and June 2010, and had been fol- Table 2) . Table 3 shows the univariable analysis of the preoperative laboratory measurements. There were increased odds of 1-year mortality in the patients with higher total bilirubin, higher activated partial thromboplastin time (aPTT), lower total protein, and lower albumin (P<0.05 for each). Categorical evaluation of these laboratory parameters showed that albumin <3.2 mg/dl (OR 8.475), total bilirubin >4.8 mg/dl (OR 7.300), aPTT >56 s (OR 5.814), and total protein <6.0 g/dl (OR 3.817) (P<0.05 for each) were risk factors for 1-year mortality. According to the multivariable analysis (Table S1), albumin <3.2 mg/dl (P=0.032) and total bilirubin >4.8 mg/dl (P=0.049) were independent risk factors associated with 1-year death after LVAD implantation among the variables of baseline characteristics and laboratory measurements.
Preoperative Laboratory Measurements
Preoperative Echocardiography and Hemodynamic Measurements
There were a few preoperative echocardiographic or hemodynamic parameters that had increased odds of 1-year death after LVAD implantation ( Table 2 . Novel Risk Score Before LVAD Implantation (ie, albumin <3.2 mg/dl, 8 points; total bilirubin >4.8 mg/dl, 7 points; LVDd <55 mm, 6 points; and CVP >11 mmHg, 5 points).
Other previously identified risk scores were also calculated and each AUC was compared by ROC analyses (Figure 1) , which demonstrated that the TVAD score was the best discriminative predictor of 1-year death after VAD implantation ( Table 5 ) (all P<0.05). As for the TVAD score, sensitivity at score 8 was 0.929, and specificity at score 18 was 0.978. To avoid device-related bias, we performed a subanalysis among patients with extracorporeal VAD implantation and the TVAD score remained the best predictor of 1-year death over other scoring system (AUC, 0.905) with high sensitivity at score 8 (0.923) and high specificity at score 18 (0.972).
Stratification of Survival by TVAD Score
We classified the patients into 3 strata according to TVAD score (ie, low (score 0-8), intermediate (score [9] [10] [11] [12] [13] [14] [15] [16] [17] , and high (score 18-26) risk strata). Figure 2A depicts the Kaplan-Meier survival curves and the 1-year survival was significantly different among 3 strata (95%, 54%, and 14%, respectively) with log-rank test (all P<0.001). According to the univariable analysis with a Cox hazard model, the hazard ratio between low and intermediate-risk strata was 11.59 and that of the high-risk stratum against the low-risk stratum was 40.10 (P<0.05 for each). Kaplan-Meier survival curves for INTERMACS profiles 1 and 2 are also shown in Figure 2A . The 1-year survival was significantly different between the 2 profiles (95.8% and 62.9%) with log-rank test (P=0.004). We also performed separate Kaplan-Meier analyses of the extracorporeal VAD group and implantable VAD group. The 1-year survival of the extracorporeal VAD group was significantly different among the 3 risk strata (P<0.001) and between the 2 profiles (P=0.008) (Figure 2B) . Patients who received implantable VADs were all assigned to the low-risk stratum (Figure 2C) .
Discussion
Based on the univariable and multivariable logistic analyses of the preoperative predictors for 1-year mortality after LVAD implantation, we constructed the TVAD score, which consisted of 4 individually weighted scores (albumin <3.2 mg/dl, total bilirubin >4.8 mg/dl, LVDd <55 mm, and CVP >11 mmHg). Among the 5 previously reported risk scores, 3-7 the TVAD score was the best discriminative predictor of 1-year postoperative death. Furthermore, the TVAD score successfully stratified the prognosis of patients after LVAD implantation. In this study, both extracorporeal and implantable VADs were implanted in patients with profile 1 or profile 2. Gener-ally speaking, those who were implanted with an extracorporeal VAD cannot be discharged from hospital and are forced to spend a low-quality life with its large driving unit. In addition to poor quality of life, the long-term prognosis itself is not very good in those patients with profile 2 after implantation of an extracorporeal VAD (3-year survival rate in our institute: 60.6%), which may largely be a result of VAD-related complications. In fact, the Kaplan-Meier curve conditional on 1year survival of patients with profile 2 resembles that of patients with profile 1 (data not shown). On the other hand, patients with profile 3-6 have had much better long-term survival rate in our institute (3-year survival rate: 85.3%) according to the VAD policy that an extracorporeal VAD should be implanted in less sick patients only when their hemodynamics deteriorate. Therefore, we consider that an extracorporeal VAD is not indicated in patients less sick than profile 2. Meanwhile, the short-term prognosis of patients with profile 2 after extracorporeal LVAD implantation in our institute has been good (1-year survival rate: 100%, Figure 2A) . We therefore believe that extracorporeal VAD implantation for patients with profile 2 was not belated. Although we now consider that patients with profile 3 are the best candidates for implantable VADs, our 10 cases of implantable VADs were all patients enrolled in clinical trials, and we could not help choosing patient with profile 2 at that time because of the limited number of enrollments.
As shown in Figure 2A , the 1-year survival rate of our patients with profile 2 was 100% after extracorporeal VAD implantation. All 10 cases of implantable VADs in this study were also assigned profile 2 (Figure 2C) , and the survival rate at 1 year was 90%. Namely, if a patient is not sicker than profile 2, postoperative recovery can fully be expected after extracorporeal VAD implantation and the survival rate at 1 year is as good as that with an implantable VAD. Profile 2 is considered to be roughly equivalent to the low-risk group having 8 or less TVAD score, and in such less sick patients the analysis of preoperative risk factors can be executed among a combined patient group with an extracorporeal VAD or an implantable VAD. Note that all patients with implantable VADs had TVAD scores less than 8 (Figure 2C) . Currently, a patient in Japan has to be listed for HTx before implantable LVAD therapy in order to secure the insurance reimbursement, and few patients with profile 1 can receive implantable VADs because there may not be enough time to prepare the listing. In this regard, most implantable VADs are indicated for patients with profile 2 or less sick, and our TVAD score is an appropriate model that also predicts the prognosis of patients with an implantable VAD under the current circumstances in Japan. Taking into consideration the abovementioned facts, preoperative factors influence the prognosis of LVAD patients during the first year regardless of device type, and we therefore determine the endpoint at 1 year after LVAD implantation.
There have been several scoring systems for predicting the prognosis of heart failure patients. Among them, the Columbia score, LM score, APACHE II score, SHFM, and INTERMACS profile have been used for LVAD patients. The Heart Failure Risk Score of Aaronson et al has also been used in LVAD patients, but was not adopted in this study because most of our patients were too sick to tolerate the exercise test necessary for their stratification. 13 The SHFM was originally constructed from data from several large-scale cohort studies of NYHA IIIB or IV patients, but did not include patients who were assigned INTERMACS profile 1 or 2. Therefore, SHFM might not be a good model for estimating the survival of such sick patients as in our study. Table 2 . Novel Risk Score Before LVAD Implantation
Rao et al concluded in the Columbia study that the patients whose score exceeded 5 points had a higher risk of perioperative mortality. 7 We did not observe a significant difference in the 1-year survival between our patients assigned >5 points and those who assigned ≤5 points (P=0.102 by log-rank test). The discrepancy may be explained by the fact that there were a few patients in our study who had a previous history of cardiac surgery (8 patients, 13.6%), which was 1 of the major attributes in the Columbia score. Leitz et al reported that higher risk patients who had >17 points in the LM score had significantly lower 1-year survival. 4 In the APACHE II score, patients who had >20 points had a significantly higher rate of in-hospital death. 6 Consistently, our patients who were assigned such high scores had a significantly worse prognosis (P=0.006 for LM score and P=0.004 for APACHE II score by log-rank test, respectively). However, both risk scores give higher points to laboratory data such as hemoglobin, platelet, sodium, potassium, and prothrombin time, which can be modified by the physician's intervention such as blood transfusion, administration of anticoagulation agents, and correction of electrolyte imbalance.
As demonstrated in a previous study, 11 the INTERMACS profile was another good predictor of 1-year death in the present study. However, its specificity for 1-year mortality was only 0.500. Moreover, this stratification is largely dependent on the physician's decision. We consider that a scoring system composed of factors that are independent of the decision or intervention by physicians is preferable. In this regard, we did not employ preoperative usage of mechanical support (IABP, PCPS, and CHDF) as a predictor in our scoring despite their higher odds. An aPTT level was also excluded from our risk stratification because the data could easily be affected by administration of heparin or other anticoagulation agents. Neither of these variables was significant in the multivariable analysis. Our patients who received RVAD concomitantly with LVAD implantation also had significantly higher 1-year mortality (OR 7.752, P=0.012) as demonstrated in other studies, 9-11 but we did not adopt this variable, because it was hard to predict during the preoperative period if a patient would eventually require BiVAD therapy.
The multivariable analysis revealed that lower albumin and higher total bilirubin were independent risk factors for 1-year mortality after LVAD implantation among many laboratory parameters. Thus, the TVAD score includes these 2 laboratory findings, which may indicate preoperative hepatic failure as a result of congestion and/or impaired circulation. Recent investigations, including our previous study, have also demonstrated that parameters reflecting end-organ dysfunction are consistent predictors of death after LVAD implantation. 4,11,13, 16 MOF was in fact the major cause of death in this study (10 patients, 71.4%). Lower albumin also reflects poor nutritional status. Holdy et al reported that malnutrition increases the risk of infection, decreases the body's ability to recover after surgery, and is associated with poor outcomes. 17 Sepsis, which 
